User login
Key clinical point: Dupilumab led to a rapid improvement in disease control that was sustained through 2 years and showed an acceptable safety profile in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD).
Major finding: Dupilumab led to an improvement in the mean Eczema Area and Severity Index score at 3 months (5.5) and 24 months (2.6) compared with baseline (16.1), with a mean absolute change from baseline to 24 months being −14.0. No new safety signals were observed.
Study details: Findings are from a 2-year interim analysis of real-world data from the PROSE registry study including 764 patients with moderate-to-severe AD (age ≥ 12 years) who initiated dupilumab.
Disclosures: The PROSE registry is sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Three authors declared being employees of or holding stock or stock options in Sanofi or Regeneron. The other authors declared serving as consultants, investigators, or advisory board members for or receiving speaker or investigator fees from Sanofi, Regeneron, and others.
Source: Simpson EL et al. Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year Interim data from the PROSE registry. Dermatol Ther (Heidelb). 2024 (Jan 4). doi: 10.1007/s13555-023-01061-4
Key clinical point: Dupilumab led to a rapid improvement in disease control that was sustained through 2 years and showed an acceptable safety profile in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD).
Major finding: Dupilumab led to an improvement in the mean Eczema Area and Severity Index score at 3 months (5.5) and 24 months (2.6) compared with baseline (16.1), with a mean absolute change from baseline to 24 months being −14.0. No new safety signals were observed.
Study details: Findings are from a 2-year interim analysis of real-world data from the PROSE registry study including 764 patients with moderate-to-severe AD (age ≥ 12 years) who initiated dupilumab.
Disclosures: The PROSE registry is sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Three authors declared being employees of or holding stock or stock options in Sanofi or Regeneron. The other authors declared serving as consultants, investigators, or advisory board members for or receiving speaker or investigator fees from Sanofi, Regeneron, and others.
Source: Simpson EL et al. Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year Interim data from the PROSE registry. Dermatol Ther (Heidelb). 2024 (Jan 4). doi: 10.1007/s13555-023-01061-4
Key clinical point: Dupilumab led to a rapid improvement in disease control that was sustained through 2 years and showed an acceptable safety profile in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD).
Major finding: Dupilumab led to an improvement in the mean Eczema Area and Severity Index score at 3 months (5.5) and 24 months (2.6) compared with baseline (16.1), with a mean absolute change from baseline to 24 months being −14.0. No new safety signals were observed.
Study details: Findings are from a 2-year interim analysis of real-world data from the PROSE registry study including 764 patients with moderate-to-severe AD (age ≥ 12 years) who initiated dupilumab.
Disclosures: The PROSE registry is sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Three authors declared being employees of or holding stock or stock options in Sanofi or Regeneron. The other authors declared serving as consultants, investigators, or advisory board members for or receiving speaker or investigator fees from Sanofi, Regeneron, and others.
Source: Simpson EL et al. Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year Interim data from the PROSE registry. Dermatol Ther (Heidelb). 2024 (Jan 4). doi: 10.1007/s13555-023-01061-4